Key Highlights

● Third-quarter Revenue was $725.4 million versus $479.5 million a year earlier.

● Adjusted EBITDA was $34.3 million, a 4.7% margin.

● The medical expense ratio was 93.0% versus 85.0% a year earlier.

● Adjusted EBITDA guidance was raised to $130.0 million to $135.0 million.

Evolent Health, Inc. (NYSE:EVH) is drawing attention as investors weigh a third-quarter report that showed sharply higher revenue alongside a lower margin. The company, released on November 5, raised its 2026 adjusted EBITDA guidance while reiterating its revenue outlook. For investors in healthcare services and value-based care, the quarter highlights how growth in risk-based arrangements can affect medical costs and margins.

Latest Company Context

Third-quarter revenue was $725.4 million versus $479.5 million a year earlier. Adjusted EBITDA was $34.3 million, a 4.7% margin, compared with $39.0 million, or 8.1%. The net loss attributable to common shareholders was $23.6 million, or $0.21 per share, versus $26.9 million, or $0.24. Adjusted income attributable to common shareholders was $7.3 million, or $0.06 per share. The medical expense ratio was 93.0% compared with 85.0% a year earlier. Average unique members were 39,804, and cash was $148.3 million at September 30. For the nine months, revenue was $1,874.1 million.

Key Business and index Drivers

Management reiterated 2026 revenue guidance of $2.6 billion to $2.7 billion, raised adjusted EBITDA guidance to $130.0 million to $135.0 million, and guided capital expenditures to $26 million to $28 million. The company announced one renewal and two new revenue agreements in the quarter, bringing the year-to-date total to seven. The renewal extended its largest Surgical Management contract four years. An existing client is expanding into oncology services across additional states covering about 1 million Commercial lives, with a January 1, 2027 go-live, and a national payer expanded oncology work into 11 additional states. The central drivers are the medical expense ratio, which reflects the risk-based revenue mix, and contract wins that support future volume.

Context matters for reading the revenue jump. Revenue rose from $479.5 million to $725.4 million, and the company's medical expense ratio rose over the same period, which is consistent with a larger share of revenue coming from arrangements in which Evolent bears medical cost risk. The company's headline guidance now implies a full-year revenue range of $2.6 billion to $2.7 billion. Member counts slipped slightly year over year, so growth in revenue was not driven by higher average membership alone.

What Investors Should Watch

Investors may watch the medical expense ratio, since it rose to 93.0% and directly affects margin. The January 1, 2027 oncology go-live and the pace of additional contract announcements are identifiable catalysts. Delivery against the raised EBITDA guidance, along with cash levels of $148.3 million, may also be monitored. Fourth-quarter results and any 2027 commentary will likely be the next detailed update. Analyst estimates are expectations rather than company guidance and could shift following the report.

Several scenarios are possible. If the higher medical expense ratio proves temporary and contract mix normalizes, margins could recover toward earlier levels; if risk-based arrangements continue to carry elevated costs, revenue growth might continue to outpace profitability. Investors may also note that Evolent does not report annual contract value, so announced agreements and management commentary are the main indicators of new business momentum. The company's quarterly filings may offer more detail on member counts, cost trends and how guidance assumptions were set for the remainder of the year.

Growth Outpaces Margins

Evolent's report combined strong revenue growth with Margin pressure, while management signaled confidence by raising its EBITDA outlook. Whether contract wins can scale without further compressing margins is a question the next few quarters may help answer.